• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home ENT

Improved overall survival with HPV positive oropharyngeal squamous cell carcinoma

byMonica ParksandAndrew Bishara
June 27, 2014
in ENT, Oncology
Reading Time: 2 mins read
Reduced HPV vaccine doses may be adequate
Share on FacebookShare on Twitter

1. Compared to HPV negative oropharyngeal squamous cell carcinoma, HPV positive tumors are associated with increased overall survival after progression of disease.

Evidence Rating Level: 2 (Good)

Study Rundown: Certain strains of human papillomavirus (HPV) are associated with oropharyngeal squamous cell carcinomas (OPCs), and HPV positive tumors have significantly reduced risk of cancer progression compared to HPV negative tumors. At the conclusion of this retrospective analysis, the authors found that positive HPV status was significantly associated with increased overall survival following local, regional or distant disease progression. Positive HPV tumor status and receipt of salvage surgery were both associated with reduced mortality after progression. Similar rates of and distribution of distant metastases were noted in both groups. Based on these results, the authors suggested that HPV status represents a significant prognostic marker in the evaluation of progressive oropharyngeal squamous cell carcinoma. However, it should be noted that the authors were unable to evaluate the effect of chemotherapy on overall survival. Furthermore, the HPV positive and negative groups had distinct demographic characteristics.

Click to read the study in JCO

Relevant Reading: Human papillomavirus and survival of patients with oropharyngeal cancer.

In-Depth [retrospective cohort study]: The authors of this retrospective analysis drew patient data from several phase III prospective clinical trials evaluating different radiotherapies in the treatment of confirmed oropharyngeal squamous cell carcinoma. A total of 181 patients were included, with 105 HPV positive and 76 HPV negative, and all had experienced local, regional, or distant disease progression. Multivariable analysis included HPV status, T stage at enrollment, progression type, salvage surgery, and pack years. The primary outcome was overall survival after disease progression. HPV positive patients were significantly more likely to be younger, Caucasian, report less cumulative cigarette exposure, and present initially with earlier tumor stages. The median time to disease progression was similar between the two groups (8.2 versus 7.3 months; p = 0.67). The mean follow-up time after progression was first noted was 4 years. On Kaplan-Meier analysis, HPV positive patients had significantly increased overall survival following progression compared to HPV negative patients (HR 0.49; 95% CI, 0.34-0.70, p < 0.001). HPV positive status (HR 0.48; 95% CI, 0.31 to 0.74) and receipt of salvage surgery (HR 0.48; 95% CI; 0.27 to 0.84) were both associated with reduced mortality after disease progression.

RELATED REPORTS

Daraxonrasib extends survival in metastatic pancreatic cancer

Molecularly guided therapy may improve outcomes in patients with unfavourable cancer of unknown primary compared with standard chemotherapy

2 Minute Medicine Rewind September 7, 2026

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: ENThpvoncologyoropharyngeal cancersquamous cell cancer
Previous Post

Novel aromatase inhibitor, ODM-201, may be safe and effective for prostate cancer

Next Post

Ultrasound, flow reserve guided coronary interventions provide minimal benefit

RelatedReports

Oncology

Daraxonrasib extends survival in metastatic pancreatic cancer

September 17, 2026
Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening
Chronic Disease

Molecularly guided therapy may improve outcomes in patients with unfavourable cancer of unknown primary compared with standard chemotherapy

September 7, 2026
Long-term outcomes for off-pump and on-pump CABG are similar
Weekly Rewinds

2 Minute Medicine Rewind September 7, 2026

September 7, 2026
Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation
Chronic Disease

Cognitive behaviour therapy may be superior to bright light therapy for insomnia in women with breast cancer undergoing chemotherapy

September 3, 2026
Next Post
Ultrasound, flow reserve guided coronary interventions provide minimal benefit

Ultrasound, flow reserve guided coronary interventions provide minimal benefit

Pre-operative transcranial magnetic stimulation useful for language mapping

Shunt settings may have little effect on intracranial pressure in hydrocephalus

Antepartum and intrapartum events both linked to neonatal HIE

Induction of labor more successful with standardization

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • The use of neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer may reduce mortality
  • Alcohol use declines but remains above pre-pandemic levels
  • High maternal egg-peanut intake not associated with reduced infant allergy
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.